AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
AAPL   396.76 (+3.41%)
FB   248.38 (+1.35%)
AMZN   3,278.40 (+2.45%)
NVDA   429.51 (+2.47%)
CGC   18.10 (+3.85%)
BABA   262.69 (+0.64%)
TSLA   1,734.66 (+12.30%)
AMD   57.34 (+2.59%)
GILD   77.18 (+1.13%)
DIS   119.48 (+0.12%)
NFLX   564.56 (+2.88%)
Log in

NASDAQ:OBSVObseva Stock Price, Forecast & News

$2.61
-0.05 (-1.88 %)
(As of 07/13/2020 10:19 AM ET)
Add
Compare
Today's Range
$2.61
Now: $2.61
$2.80
50-Day Range
$2.79
MA: $4.96
$6.15
52-Week Range
$1.63
Now: $2.61
$11.08
Volume14,539 shs
Average Volume1.55 million shs
Market Capitalization$126.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Read More
Obseva logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.01 per share

Profitability

Net Income$-108,790,000.00

Miscellaneous

Employees43
Market Cap$126.77 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

Obseva (NASDAQ:OBSV) Frequently Asked Questions

How has Obseva's stock been impacted by COVID-19 (Coronavirus)?

Obseva's stock was trading at $2.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OBSV shares have increased by 1.6% and is now trading at $2.61. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Obseva?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Obseva.

When is Obseva's next earnings date?

Obseva is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Obseva.

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) released its earnings results on Tuesday, May, 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.00. View Obseva's earnings history.

What price target have analysts set for OBSV?

7 brokerages have issued 1 year target prices for Obseva's stock. Their forecasts range from $4.00 to $36.00. On average, they anticipate Obseva's stock price to reach $14.71 in the next twelve months. This suggests a possible upside of 463.8% from the stock's current price. View analysts' price targets for Obseva.

Has Obseva been receiving favorable news coverage?

News headlines about OBSV stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Obseva earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Obseva.

Are investors shorting Obseva?

Obseva saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 799,000 shares, an increase of 24.1% from the June 15th total of 644,000 shares. Based on an average daily trading volume, of 705,300 shares, the short-interest ratio is presently 1.1 days. Approximately 2.7% of the company's shares are short sold. View Obseva's Current Options Chain.

Who are some of Obseva's key competitors?

What other stocks do shareholders of Obseva own?

Who are Obseva's key executives?

Obseva's management team includes the following people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $2.61.

How big of a company is Obseva?

Obseva has a market capitalization of $126.77 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Obseva employs 43 workers across the globe.

What is Obseva's official website?

The official website for Obseva is www.obseva.com.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.